This startup develops a non-invasive neurostimulation therapy for sleep apnea. Their therapy delivery system opens the airway, addressing the root cause of sleep apnea and allowing patients to sleep peacefully.
Funding
Funding not disclosed
Founders
Product
Problem
Obstructive sleep apnea (OSA) affects millions, increasing the risk of heart attack, stroke, and diabetes. Current treatments are often invasive, ineffective, and poorly tolerated, with a high failure rate for CPAP therapy.
Solution
Somnair is developing a non-invasive neurostimulation device designed to treat obstructive sleep apnea by addressing its root cause. The device uses a proprietary therapy delivery system to open the airway, allowing for more restful sleep. This neurostimulation therapy is designed to be non-invasive and deployed at home, offering a convenient alternative to existing treatments.
Target Audience
The primary target audience includes individuals suffering from obstructive sleep apnea and clinicians seeking alternative treatment options to CPAP.
Features
- Non-invasive neurostimulation technology
- Proprietary therapy delivery system for opening the airway
- Designed for convenient at-home use